3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Stomach Neoplasms
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neoplasms, Unknown Primary
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Colorectal Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Cisplatin
5
Carboplatin
5
Cyclophosphamide
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
pembrolizumab
3
Oxaliplatin
3
Magnetic Resonance Spectroscopy
3
Leucovorin
3
Irinotecan
3
Gemcitabine
3
Fluorouracil
3
Docetaxel
3
Capecitabine
3
tislelizumab
2
fludarabine
2
Specimen Handling
2
Riluzole
2
Quality of Life
2
Psychiatric Rehabilitation
2
Oncolytic Virotherapy
2
Observation
2
Fluorodeoxyglucose F18
2
Fluorescein
2
Floxuridine
2
Filgrastim
2
Drug Therapy
2
Cetuximab
2
umbralisib
1
trifluridine tipiracil drug combination
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Stomach Neoplasms
×
Poly(ADP-ribose) Polymerase Inhibitors
×
Sarcoma
×
Clear all
NCT04584008
2024-10-15
VISIONARY
Peking University
Phase NA
Active not recruiting
600 enrolled